Work

Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models

Year: 2023

Type: article

Source: British Journal of Cancer

DOI: 10.1038/s41416-023-02359-y

Authors: Xin Li, Yanhua Chen, Lijuan Bai, Rui Zhao, Yifei Wu, Zhong-Ru Xie, Jason M. Wu, Nathan J. Bowen, Alira Danaher, Nicholas Cook, Dehong Li, Min Qui, Yuhong Du, Haian Fu, Adeboye O. Osunkoya, Omer Kucuk, Daqing Wu

Institutions: Augusta University, Clark Atlanta University, Wuhan Union Hospital, Huazhong University of Science and Technology, Jilin University, University of Georgia, Emory University, Winship Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, U.S. Department of Education, Emory University, Georgia Research Alliance, Augusta University, National Institutes of Health, National Cancer Institute, National Institute on Minority Health and Health Disparities

Awards: G1856198085, G2077474143, G2339076023, Small-molecule therapy for metastatic castration-resistant prostate cancer, G4063425892, G5805383984, G6431027115, G6663836133, Targeting chemoresistant prostate cancer with novel EED inhibitors, Enhancement of Cancer Research at Clark Atlanta University

OpenAlex ID: W4384924294

FWCI: 1.424

Cites: 61

Cited by: 9

Related to: 10